15-min delayed · Aug 25, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 1 firms covering Marker Therapeutics Inc, 1 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. Targets are tightly clustered, $10.00 to $10.00, so the covering firms are broadly aligned. The average target of $10.00 sits 554% above the current $1.53. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.17 next quarter toward $-0.53 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS1 ratings
Strong Buy
Strong Buy00%
Buy1100%
Hold00%
Sell00%
Strong Sell00%
Based on 1 analysts giving stock ratings to Marker Therapeutics Inc.
As of Aug, 1 of 1 firms rate MRKR a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
MRKR EPS & revenue forecast
EPS · NEXT QUARTER
$-0.17
Range $-0.22 – $-0.12 · 2 analysts · +325% YoY
Next period, 2 analysts expect Marker Therapeutics Inc to earn $-0.17 a share (range $-0.22 – $-0.12), versus $-0.04 a year earlier. Full-year consensus is $-0.56, growing to $-0.53 the year after.
REVENUE · NEXT QUARTER
$715.3K
Range $0 – $1.4M · 2 analysts · -35% YoY
Revenue is expected to reach $715.3K (range $0 – $1.4M), -35.2% year-over-year. Full-year consensus is $4.2M, rising to $20.2M next year.
Top analysts covering Marker Therapeutics Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on MRKR.
#1
Patrick R. Trucchio
HC Wainwright & Co. · Rank #234
Buy
$10.00+553.6% to target
Overall win rate
36%
+ Follow
#2
John Newman
Canaccord Genuity · Rank #402
Buy
$8.00+422.9% to target
Overall win rate
30%
+ Follow
#3
Aydin Huseynov
Ladenburg Thalmann · Rank #422
Buy
$19.00+1141.8% to target
Overall win rate
34%
+ Follow
#4
SB
Steve Brozak
WBB Securities
Buy
$12.50+717.0% to target
Coverage
—
+ Follow
MRKR stock forecast FAQ
What is MRKR's average 12-month price target?+
The 1 analysts with a live target average $10.00 for Marker Therapeutics Inc over the next 12 months, ranging from a $10.00 high to a $10.00 low.
Is MRKR stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 1 analyst ratings, 1 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
How many Wall Street analysts cover MRKR?+
1 analysts have an active rating on Marker Therapeutics Inc, and 1 firms carry a live 12-month price target.
Who is the most accurate analyst covering MRKR?+
Among analysts who currently cover MRKR, Patrick R. Trucchio of HC Wainwright & Co. has the strongest overall Quantellect track record (Rank #234). Their current call is Buy with a $10.00 target.
What is Marker Therapeutics Inc's projected EPS for next quarter?+
The consensus estimate is $-0.17 per share (range $-0.22 – $-0.12) across 2 analysts. Full-year EPS is projected at $-0.56, rising to $-0.53 the following year.
How much revenue is Marker Therapeutics Inc expected to report next quarter?+
Consensus revenue is $715.3K (range $0 – $1.4M). Full-year revenue is projected at $4.2M, growing to $20.2M next year.
Have analysts been upgrading or downgrading MRKR lately?+
As of Aug, 1 of 1 firms rate MRKR a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their MRKR calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
